Market Overview

GW Pharmaceutical's Upcoming Epidiolex Data Has Relatively Low Bar for Success

Share:
Related GWPH
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
What Is CBD — And How Can Investors Take Advantage Of It?
European advisory group backs GW Pharma's Epidiolex (Seeking Alpha)

On Tuesday, Leerink reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ: GWPH) and $79 price target.

Analyst Joseph Schwartz believes the “bar for success is relatively low” for upcoming Epidiolex data, based on the review of epilepsy trials. Schwartz went on to explain that 20 to 50 percent reduction in seizures versus placebo is generally good enough to approve add-on treatments.

In the second half of 2014, the company will start placebo-controlled proof-of-concept study followed by studies in Dravet and Lennox-Gastaut syndrome in 2015.

Shares closed up 1.5 percent to $66.19 in Tuesday's trading.

Latest Ratings for GWPH

DateFirmActionFromTo
Nov 2018Leerink SwannInitiates Coverage OnOutperform
Oct 2018Morgan StanleyMaintainsOverweightOverweight
Sep 2018Morgan StanleyReinstatesOverweight

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Joseph Schwartz LeerinkAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GWPH)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

#PreMarket Primer: Wednesday, March 26: Markets Recover On Positive US Data

UPDATE: UBS Downgrades Navistar International Corporation to Neutral, Lowers PT to $36.00